Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.
Epistemonikos ID: 32bb21136d0385eccc90ea870ac5fdd6948179c9
First added on: Apr 16, 2025